SG Americas Securities
LBRX

SG Americas Securities’s LB Pharmaceuticals LBRX Stock Holding History

SG Americas Securities’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,434
Closed -$143K – 3828
2025
Q4 		$143K Buy
+6,434
New +$112K ﹤0.01% 3070

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

SG Americas Securities's LBRX Position: Q1 2026 in Review

SG Americas Securities sold out of LB Pharmaceuticals (LBRX) in Q1 2026, closing a stake of 6,434 shares — an estimated $143K sold.

SG Americas Securities first reported a position in LBRX in Q4 2025 and held it in 1 quarter. The position peaked at $143K in Q4 2025. 77 funds tracked by Wall St. Rank hold LBRX as of Q1 2026.

  • SG Americas Securities reported no remaining LB Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • SG Americas Securities sold 6,434 LB Pharmaceuticals shares in Q1 2026, an estimated $143K.
  • SG Americas Securities first reported a position in LB Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • SG Americas Securities's LB Pharmaceuticals position peaked at $143K in Q4 2025.
  • 77 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.